Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

red-green color blindness - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

red-green color blindness

MONDO:0010564

Also known as:Deutan defectcolorblindness, deutandeuteranopia

Overview

Deuteranopia is a type of color vision deficiency where the green photoreceptors are absent. It affects hue discrimination in the same way as protanopia, but without the dimming effect. Like protanopia, it is hereditary, sex-linked, and found in about 1% of the male population.

GeneticsX-linked · OPN1MW (chr X)

Clinical Presentation

Features include: Deuteranomaly.

Explore clinical features

Genetic Landscape

Assembled from HGNC gene records, ClinGen gene-disease validity evidence, and ClinVar pathogenic variant data. Validity classifications reflect the strength of published evidence linking each gene to this disease.

OPN1MW encodes opsin 1, medium wave sensitive (364 aa). Visual pigments are the light-absorbing molecules that mediate vision. They consist of an apoprotein, opsin, covalently linked to cis-retinal Highest expression in Adipose Subcutaneous (0.0 TPM) and Adipose Visceral Omentum (0.0 TPM).

Red-green color blindness is caused by mutations in the OPN1MW gene on chromosome X.

The OPN1MW protein participates in Defective OPN1MW does not bind 11cRAL, Light stimulates opsin receptors, and OPN1MW LOF variants pathways.

OPN1MW is classified as a druggable target (Druggable Genome and G Protein Coupled Receptor categories) with score 6.5.

Diagnosis

Genetic testing for OPN1MW is available. Testing is considered confirmatory for diagnosis.

Biomarker and diagnostic research for red-green color blindness has been reported in the published literature.

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

No clinical trials have been registered for red-green color blindness.

22 publications have been identified in PubMed for red-green color blindness. Research spans Basic Science / Preclinical (36%), Diagnostic / Biomarker (18%), and Clinical Trial Publication (14%).

Research Type	Count	% of Total
Laboratory research	8	36%

Data assembled from 7 of 12 sources · Last updated Sep 19, 2026, 9:39 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

OMIM

Online Mendelian Inheritance in Man

OMIM:303800

Orphanet

European rare disease database

Orphanet:319698

Questions for Your Care Team

→Should female family members consider carrier screening for OPN1MW?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

red-green color blindness

Overview

Clinical Presentation

Explore clinical features

Genetic Landscape

Diagnosis

Research Landscape

Medical References

External Resources

OMIM

Orphanet

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Recent Publications